IQV stock sentiment todayIQVIA Holdings Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 78% confidence.
Last updated · cached analysis, refreshes periodically
IQV
IQVIA Holdings Inc.IQVIA is a high-quality market leader navigating a complex debt restructuring phase while facing short-term valuation resistance.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for IQV. Not financial advice.
Price · last 12 months
Gossip
The market is currently digesting a major $2 billion debt refinancing move aimed at cleaning up the balance sheet. While analysts remain generally positive on the long-term AI-driven 'Predictive Clinical Development' narrative, recent insider selling and GF Value warnings suggest the stock may be reaching a temporary local ceiling.
- ·Large-scale $2B senior notes offering to manage interest expenses
- ·Expansion into AI-driven predictive analytics for clinical trials
- ·Concerns over immediate valuation premiums (overvalued by ~4%)
- ·Slightly bearish insider selling activity by executives
Financial
IQV maintains a dominant market position in CRO and healthcare data, characterized by high recurring revenue and robust margins. However, high leverage remains a focal point, hence the recent bond issuance to term out debt.
- ·LTM Revenue: ~$15.1B with steady mid-single-digit growth
- ·EBITDA Margins: Strong ~22-24% range
- ·Net Debt/EBITDA: ~3.4x, prompting recent refinancing efforts
- ·Free Cash Flow: Strong conversion (~80-90% of Adjusted Net Income)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·Insiders sold a net $29.9M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Exposure to biotech funding cycles affecting R&D spend
- ·Interest rate sensitivity due to significant debt load
- ·Integration risks associated with aggressive M&A and tech-stack pivots
Peer temperature
How direct competitors stack up against IQV right now.
- HOTMEDPMedpace Holdings
HOTTER — Superior organic growth rates and zero debt balance sheet compared to IQV's leveraged structure.
See full analysis → - NEUTRALICONICON plc
COUSIN — Similar scale and valuation, but currently seeing slightly better book-to-bill momentum in clinical research.
See full analysis → - COLDFTVFortive Corporation
COLDER — Lower exposure to the high-growth life sciences data niche and facing headwinds in its broader industrial tech segments.
See full analysis →
- IQV+7.1%
- MEDP-1.9%
- ICON-12.3%
- FTV-8.5%
Analyst price target
Consensus average of 15 analysts · median 275.00
Source: StockAnalysis.com · updated 2026-08-12
Recent headlines
- simplywall.stIQVIA Holdings (IQV) Launched Predictive Clinical Development, Is The Stock Cheap Or Pricey?
- Stock TitanIQVIA (NYSE: IQV) plans $2B notes sale to redeem 2026 bonds and reduce credit-line debt
- GuruFocusIQV Looks 4.4% Overvalued on GF Value™ as Senior Notes Offering Unfolds
- Yahoo! Finance CanadaIQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings?
- TradingViewIQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings?
- DirectorsTalk InterviewsIQVIA Holdings, Inc. (IQV) Stock Analysis: Strong Analyst Consensus with 3.18% Potential Upside
AI-generated analysis for informational purposes only. Not financial advice.